Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Sensex down 2% on weak cues
Mon, 29 Jun 09:30 am

Share prices began to plummet across Asia on Monday as hopes dwindled for a resolution to the Greek debt crisis. Japan's Nikkei stock average briefly fell by more than 500 points in early trading, while the euro dropped more than 3%. More than US$35bn was wiped off the Australian stock market in the first hour of trading on Monday.

Meanwhile, the Sensex is down by around 502 points (down 1.8%), while the NSE-Nifty is down by around 147 points (down 1.75%). Mid and small cap stocks are trading equally in the red with the BSE Mid Cap and BSE Small Cap indices down by around 2.3% each. Losses were largely seen in realty and banking stocks. The Indian Rupee has opened lower by 20 paise at 63.84 per dollar versus Friday's closing of 63.64.

According to a leading financial daily, In a bid to raise around Rs 18 bn, the Government is planning to sell 3% stake in Bharat Petroleum Corporation (BPCL), the nation's second largest state oil firm, in FY16. In this regard, the Finance Ministry has moved a Cabinet note for inter-ministerial consultations for selling 21.6 m shares in BPCL through a public offer. The stake sale will fetch the Government over Rs 17.78 bn. The Government holds 54.93% stake in BPCL. The Government is targeting Rs 695 bn from stake sale in PSUs in FY16. Of this, Rs 410 bn is to come from minority share sale in PSUs and Rs 285 bn from strategic stake sale.

Stocks in have opened the trading day on a negative note with Wockhardt Ltd and Opto Circuits bearing most of the brunt. According to a leading financial daily, the government plans to set up Rs 5 bn venture capital funds to boost domestic pharma industry and provide cheaper loans to entities looking to establish or upgrade manufacturing facilities. The government is working on various proposals, including single window clearance for drug approvals, to rejuvenate the local pharma sector and make medicines more affordable. The steps were suggested by a task force formed by the Department of Pharmaceuticals (DoP) in a report submitted to Chemicals and Fertilizers Minister. This is in line with the government's agenda of promoting 'Make in India'. In the report, the task force had also said the DoP may also come up with seed capital and facilitate funding with other financial institutions for the medium and small scale pharmaceuticals industry.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Sensex down 2% on weak cues". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.